New Delhi: Eminent cardiologist Dr Ashok Seth was recently invited to give a presentation before a US Food and Drug Administration (FDA) advisory panel on the safety and efficacy of Abbot Laboratories’ ‘Absorb Bioresorbable Vascular Scaffold’ (ABVS), or what is commonly known as a stent that melts away after doing its job, in tackling blockages in the coronary arteries.
Dr Ashok Seth, chairman of Fortis Escorts Heart Institute, New Delhi, presented his experience and perspectives on the use of bioresorbable stents before the FDA panel in Washington on March 15 and after a whole day of presentation and discussion, the panel on the same evening voted in favour of approval of ABVS.
“This is a great step forward for treating CAD (coronary artery disease),” Dr Seth told India Medical Times.
Dr Seth, who has one of the largest experiences with the use of bioresorbable stents in the world, said, “It was the first time ever that a doctor from India and working in India had presented before the FDA panel.”
According to Dr Seth, he was one of the four international experts — the others were from Holland, Germany and Brazil — who gave their presentation on ABVS before the FDA panel.
It is believed that around 17,000 bioresorbable stents have been used in India since its introduction in the country in December 2012. Dr Seth alone has used around 1,200 so far.